ANRO
$22.36
Alto Neuroscience, Inc.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It...
Recent News
Alto Neuroscience, Inc.'s (NYSE:ANRO) Intrinsic Value Is Potentially 58% Above Its Share Price
Key Insights The projected fair value for Alto Neuroscience is US$23.71 based on 2 Stage Free Cash Flow to Equity Alto...
Alto Neuroscience, Inc. (NYSE:ANRO) is definitely on the radar of institutional investors who own 33% of the company
Key Insights Given the large stake in the stock by institutions, Alto Neuroscience's stock price might be vulnerable to...
Is Alto Neuroscience, Inc. (ANRO) Outperforming Other Medical Stocks This Year?
Here is how Alto Neuroscience, Inc. (ANRO) and Editas Medicine (EDIT) have performed compared to their sector so far this year.
Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates?
Alto Neuroscience, Autolus Therapeutics, Ascendis Pharma and Immuneering are gearing up to report Q3 results that could top expectations.
How Much Upside is Left in Alto Neuroscience, Inc. (ANRO)? Wall Street Analysts Think 61.99%
The consensus price target hints at a 62% upside potential for Alto Neuroscience, Inc. (ANRO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.